Company Filing History:
1 out of 111 
1 out of 5,094 
1 out of 4 Years Active: 2019
Title: David Gilot: Innovator in Melanoma Research
Introduction
David Gilot is a prominent inventor based in Goven, France. He has made significant contributions to the field of melanoma research, particularly through his innovative approaches to treatment and patient management. His work focuses on the use of natural miRNA sponges to combat human melanoma aggressiveness.
Latest Patents
David Gilot holds a patent for TYRP1, a natural miRNA sponge, and its application in managing human melanoma aggressiveness. This invention relates to methods and reagents for treating melanoma and metastatic melanoma by targeting the TYRP1 RNA transcript. Additionally, it includes methods for predicting a melanoma patient's therapeutic response and assessing the effectiveness of treatment methods. The invention also identifies a combination of biological markers that can predict the survival of melanoma patients, regardless of the treatment administered.
Career Highlights
Throughout his career, David Gilot has worked with esteemed institutions such as Université de Rennes 1 and the Centre National de la Recherche Scientifique. His research has been pivotal in advancing the understanding of melanoma and improving treatment strategies.
Collaborations
David has collaborated with notable colleagues, including Marie-Dominique Galibert and Ghanem Ghanem. Their joint efforts have contributed to the development of innovative solutions in melanoma research.
Conclusion
David Gilot's work exemplifies the intersection of innovation and medical research, particularly in the fight against melanoma. His contributions through patents and collaborations continue to influence the field and offer hope for improved patient outcomes.